alpha-aminopyridine has been researched along with Autoimmune Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aan de Kerk, DJ; Beijersbergen, RL; Jansen, MH; Kuijpers, TW; Lieftink, C; Morris, B; Tuijnenburg, P; van Leeuwen, EMM | 1 |
| Bogdanos, DP; Mavropoulos, A; Sakkas, LI | 1 |
| Hata, T; Iwasaki, H; Kato, T; Kobayashi, H; Matsuo, A; Matsushita, M; Ohta, T | 1 |
| DeMartino, J; Hermann, J; Hsu, J; Hu, DQ; Kim, Y; Liao, C; Lucas, M; Lukacs, C; Menke, J; Narula, S; Pashine, A; Romero, N; Slade, M; Tan, SL; Truitt, T; Whittard, T; Xu, D; Zhang, J; Zhou, M | 1 |
| Bähr, M; Diem, R; Neusch, C; Otto, M; Pehlke, JR; Sättler, MB; Williams, SK | 1 |
| Kapoor, S | 1 |
| Lundh, H; Nilsson, O; Rosén, I | 1 |
1 review(s) available for alpha-aminopyridine and Autoimmune Disease
| Article | Year |
|---|---|
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Humans; Immunologic Factors; Intestinal Diseases; Phosphodiesterase 4 Inhibitors; Skin Diseases; Thalidomide | 2017 |
6 other study(ies) available for alpha-aminopyridine and Autoimmune Disease
| Article | Year |
|---|---|
High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.
Topics: Aminopyridines; Antibody Formation; Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Cell Differentiation; Drug Discovery; High-Throughput Screening Assays; Humans; Lymphocyte Activation; Morpholines; Plasma Cells; Protein Kinase Inhibitors; Purines; Sirolimus; TOR Serine-Threonine Kinases | 2020 |
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Topics: Aminopyridines; Animals; Arthritis, Experimental; Autoimmune Diseases; Autoimmunity; Cells, Cultured; Disease Models, Animal; Female; Humans; Immunoglobulin G; Male; Mast Cells; Monocytes; Passive Cutaneous Anaphylaxis; Protein Kinase Inhibitors; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar; Syk Kinase; Thiazoles | 2017 |
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Topics: Adaptive Immunity; Administration, Oral; Aminopyridines; Animals; Arthritis, Experimental; Autoimmune Diseases; B-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Flow Cytometry; Humans; Immunity, Innate; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Models, Molecular; Molecular Structure; Osteoclasts; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyridazines; Signal Transduction; Small Molecule Libraries; Syk Kinase | 2013 |
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Topics: Aminopyridines; Animals; Autoimmune Diseases; Cell Survival; Cells, Cultured; Cytoprotection; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Female; Inflammation; Interferon-beta; Ion Channel Gating; Neuroprotective Agents; Optic Nerve; Optic Neuritis; Potassium Channels, Inwardly Rectifying; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred BN; Rats, Wistar; Retinal Ganglion Cells | 2008 |
Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Topics: Aminopyridines; Autoimmune Diseases; Diabetes Mellitus, Type 2; Glomerulonephritis; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Reperfusion Injury; Signal Transduction; Spleen; Syk Kinase | 2011 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Aged; Myasthenia Gravis; Pyridostigmine Bromide; Syndrome | 1984 |